SEC Form 4 · accession 0001140361-15-010971

INTERPACE BIOSCIENCES, INC. · IDXG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO · Director

Period of report

Mar 5, 2015

Accepted (ET)

Mar 9, 2015 · 4:40 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001054102

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Mar 5, 2015	A	444,364	$1.73	A	871,681	D
Common stock^F1	holding	—	—		—	427,317	D
Common Stock	holding	—	—		—	55,000	I	by IRA
Common Stock	holding	—	—		—	1,000	I	By Self as Custodian for Daughters
Common Stock	holding	—	—		—	50,000	I	By Spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Appreciation Rights^F3	$6.41	holding	—	—	—	—	Jan 31, 2017	Common stock	111,684	111,684	D
Stock Appreciation Rights^F4	$5.44	holding	—	—	—	—	Apr 4, 2018	Common Stock	141,700	253,384	D
Stock Appreciation Rights^F5	$5.10	holding	—	—	—	—	Feb 26, 2019	Common Stock	177,665	431,049	D
Stock Appreciation Rights^F6	$5.10	holding	—	—	—	—	Feb 26, 2019	Common Stock	188,165	619,214	D

F1Includes 51,320 restricted shares of common stock that vest on April 4, 2016 and 63,177 restricted shares of common stock that vest on February 26, 2017.
F2Restricted shares of common stock that vest on March 5, 2018.
F3Currently exercisable.
F4Stock appreciation rights that are currently one-third vested, and the remaining two-thirds vest one-half on each of 4/4/15 and 4/4/16.
F5Stock appreciation rights that are currently one-third vested and the remaining two-thirds vest one-half on each of 2/26/16 and 2/26/17.
F6Performance contingent stock appreciation rights ("SARs"). There are 36,496 SARs currently vested. The remaining SARs vest as follows: 64,460 on 2/26/16 and 87,209 on 2/27/17. The SARs are only exercisable if the performance conditions are met.